Cutia Therapeutics

HKSE 2487.HK

Cutia Therapeutics Interest Coverage Ratio for the year ending December 31, 2023: -437.63

Cutia Therapeutics Interest Coverage Ratio is -437.63 for the year ending December 31, 2023, a -36.48% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Cutia Therapeutics Interest Coverage Ratio for the year ending December 31, 2022 was -320.66, a 43.81% change year over year.
  • Cutia Therapeutics Interest Coverage Ratio for the year ending December 31, 2021 was -570.70.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
HKSE: 2487.HK

Cutia Therapeutics

CEO Ms. Lele Zhang
IPO Date June 12, 2023
Location China
Headquarters Huanzhi Building
Employees 360
Sector Health Care
Industries
Pharmaceuticals Biotechnology Cosmetics
Description

Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.

StockViz Staff

January 16, 2025

Any question? Send us an email